Targets › GGTA1
4 programs from 3 companies in 4 trials: 3 Phase 1, 1 Phase 2; Genitourinary, Oncology; next expected readout Jan 2028.
Open in Phaseline: the race on GGTA1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Prescient Therapeutics | PTX-100 Peptidomimetic inhibitor of GGTase 1 | GGTA1 | Phase 2 | CTCL | Jan 2028 |
| Xeno Holdings (US), LLC dba ChoironeX | ChoironeX GalKO Porcine Thymokidney Genetically modified porcine thymokidney with knockout of alpha-gal epitope (GalKO) for xe | GGTA1 | Phase 1 | End Stage Renal Disease | Jun 2028 |
| United Therapeutics | 10 GE Xenokidney Porcine-derived kidney with intentional genomic alterations (knockout of GGTA1, CMAH, BHMT | GGTA1, CMAH, BHMT, PERV | Phase 1 | ESRD (End-Stage Renal Disease) | Oct 2028 |
| United Therapeutics | GGTA1 KO Thymokidney Porcine kidney with GGTA1 gene knockout (xenotransplant) combined with thymic tissue autog | GGTA1 | Phase 1 | ESRD (End-Stage Renal Disease) | Nov 2029 |
ESRD (End-Stage Renal Disease) (2) End Stage Renal Disease (1) CTCL (1)
protein or peptide (3), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.